Previous Close | 1.2900 |
Open | 1.3000 |
Bid | 1.2500 x 1400 |
Ask | 1.3200 x 1000 |
Day's Range | 1.2543 - 1.3206 |
52 Week Range | 1.0000 - 4.1900 |
Volume | |
Avg. Volume | 1,205,722 |
Market Cap | 24.019M |
Beta (5Y Monthly) | 2.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.2960 |
Earnings Date | May 13, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present in-person at the H.C. Wainwright Global Investment Conference, on May 24, 2022 in Miami, Florida.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced that Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, today presented BiondVax's progress, achieving certain milestones, under its nanosized antibodies (NanoAbs) program.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.